Blue Jay Capital Management adds Vertex Pharmaceuticals Incorporated (VRTX) to its portfolio

Vertex Pharmaceuticals Incorporated (VRTX) : Blue Jay Capital Management added new position in Vertex Pharmaceuticals Incorporated during the most recent quarter end. The investment management firm now holds 125,450 shares of Vertex Pharmaceuticals Incorporated which is valued at $12,736,939 , the company said in a statement filed on Aug 12, 2016 with the SEC.Vertex Pharmaceuticals Incorporated makes up approximately 7.55% of Blue Jay Capital Management’s portfolio.

Other Hedge Funds, Including , Argentus Capital Management sold out all of its stake in VRTX during the most recent quarter. The investment firm sold 2,318 shares of VRTX which is valued $235,347.Credit Suisse Ag boosted its stake in VRTX in the latest quarter, The investment management firm added 83,126 additional shares and now holds a total of 702,785 shares of Vertex Pharmaceuticals Incorporated which is valued at $71,353,761. Vertex Pharmaceuticals Incorporated makes up approx 0.09% of Credit Suisse Ag’s portfolio. Trexquant Investment Lp sold out all of its stake in VRTX during the most recent quarter. The investment firm sold 11,500 shares of VRTX which is valued $1,167,595.

Vertex Pharmaceuticals Incorporated closed down -0.15 points or -0.15% at $96.94 with 5,95,225 shares getting traded on Monday. Post opening the session at $97.48, the shares hit an intraday low of $95.57 and an intraday high of $97.77 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.

On the company’s financial health, Vertex Pharmaceuticals Incorporated reported $0.24 EPS for the quarter, beating the analyst consensus estimate by $ 0.04 according to the earnings call on Jul 27, 2016. Analyst had a consensus of $0.20. The company had revenue of $431.61 million for the quarter, compared to analysts expectations of $429.58 million. The company’s revenue was up 159.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.54 EPS.

Many Wall Street Analysts have commented on Vertex Pharmaceuticals Incorporated. Shares were Reiterated by Stifel on Aug 16, 2016 to “Buy” and Lowered the Price Target to $ 105 from a previous price target of $108 .

Vertex Pharmaceuticals Incorporated (Vertex) is a global biotechnology company. The Company is engaged in the business of discovering developing manufacturing and commercializing small molecule drugs. The Company uses precision medicine approaches to create transformative drugs for patients with serious diseases in specialty markets. Vertex’s business is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF). It is also engaged in other research and early-stage development programs including programs in the areas of oncology and neurology. The Company’s product candidates include KALYDECO (ivacaftor) Lumacaftor in combination with Ivacaftor VX-661 in combination with Ivacaftor VX-803 VX-970 and VX-222. The Company’s product KALYDECO is available in the market.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *